Publikationen im NUM
Hier finden Sie eine Liste der Publikationen, die im Zusammenhang mit dem Netzwerk Universitätsmedizin in der ersten und zweiten Förderphase entstanden sind.
J. Trimpert and
et al,
"Deciphering the Role of Humoral and Cellular Immune Responses in Different COVID-19 Vaccines-A Comparison of Vaccine Candidate Genes in Roborovski Dwarf Hamsters",
Viruses,
vol. 13,
2021.
| DOI: | 10.3390/v13112290 |
M. Schwabenland,
H. Salié,
J. Tanevski,
S. Killmer,
M. Lago,
A. Schlaak,
L. Mayer,
J. Matschke,
K. Püschel,
A. Fitzek,
B. Ondruschka,
H. Mei,
T. Boettler,
C. Neumann-Haefelin,
M. Hofmann,
A. Breithaupt,
N. Genc,
C. Stadelmann,
J. Saez-Rodriguez,
P. Bronsert,
K. Knobeloch,
T. Blank,
R. Thimme,
M. Glatzel,
M. Prinz and
B. Bengsch,
"Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions",
Immunity,
vol. 54,
no. 7,
pp. 1594-1610.e11,
2021.
| DOI: | 10.1016/j.immuni.2021.06.002 |
T. Schwarz and
et al,
"Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany",
Emerging infectious diseases,
vol. 27,
2021.
| DOI: | 10.3201/eid2708.211145 |
N. -. Hoff and
et al,
"Delayed skin reaction after mRNA-1273 vaccine against SARS-CoV-2: a rare clinical reaction",
European Journal of Medical Research,
vol. 26,
pp. 98,
2021.
| DOI: | 10.1186/s40001-021-00557-z |
P. Arora and
et al,
"Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance",
Cellular & Molecular Immunology,
vol. 18,
pp. 2557—2559,
2021.
| DOI: | 10.1038/s41423-021-00772-y |
M. Baumann,
M. Berghäuser,
T. Bolz and
T. Martens,
"Den Fokus neu denken - Skizze eines Pandemiemanagements auf Grundlage der Bedürfnisse und Lern- und Entwicklungserfordernissen von Kindern, Jugendlichen und Familien",
2021.
J. Holz,
"Der Erfolg Vietnams im Kampf gegen das Virus",
Südostasien. Zeitschrift für Politik, Kultur, Dialog,
Feb.
2021.
M. Casagrande,
A. Fitzek,
M. Spitzer,
K. Püschel,
M. Glatzel,
S. Krasemann,
M. Aepfelbacher,
D. Nörz,
M. Lütgehetmann,
S. Pfefferle and
M. Schultheiss,
"Detection of SARS-CoV-2 genomic and subgenomic RNA in retina and optic nerve of patients with COVID-19",
Br J Ophthalmol,
vol. 105,
no. 8,
pp. 1057-1061,
2021.
M. Döpfner,
J. Adam,
C. Habbel and
et al,
"Die psychische Belastung von Kindern und Jugendlichen und ihren Familien während der COVID-19-Pandemie und der Zusammenhang mit emotionalen und Verhaltensauffälligkeiten",
Bundesgesundheitsbl,
vol. 64,
2021.
| DOI: | 10.1007/s00103-021-03455-1 |
M. Döpfner,
J. Adam,
C. Habbel,
B. Schulte,
K. Schulze-Husmann,
M. Simons,
F. Heuer,
C. Wegner,
S. Bender,
B. Herpertz-Dahlmann and
others,
"Die psychische Belastung von Kindern, Jugendlichen und ihren Familien während der COVID-19-Pandemie und der Zusammenhang mit emotionalen und Verhaltensauffälligkeiten",
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz,
vol. 64,
no. 12,
pp. 1522—1532,
2021.
| DOI: | 10.1007/s00103-021-03455-1 |
A. Schuppert,
K. Polotzek,
J. Schmitt,
R. Busse,
J. Karschau and
C. Karagiannidis,
"Different spreading dynamics throughout Germany during the second wave of the COVID-19 pandemic: A time series study based on national surveillance data",
The Lancet Regional Health - Europe,
vol. 6,
pp. 100151,
2021.
| DOI: | 10.1016/j.lanepe.2021.100151 |
| Datei: | https://doi.org/10.1016/j.lanepe.2021.100151 |
K. F. Ahrens,
R. J. Neumann,
B. Kollmann,
M. M. Plichta,
K. Lieb,
O. Tüscher and
A. Reif,
"Differential impact of COVID-related lockdown on mental health in Germany",
World Psychiatry,
vol. 20,
no. 1,
pp. 140—141,
2021.
| DOI: | 10.1002/wps.20830 |
K. Vanshylla and
et al,
"Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers",
Cell host & microbe,
2021.
| DOI: | 10.1016/j.chom.2021.12.010 |
S. Schlickeiser,
T. Schwarz,
S. Steiner,
K. Wittke,
N. Al Besher,
O. Meyer,
U. Kalus,
A. Pruß,
F. Kurth,
T. Zoller and
others,
"Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses",
Front Immunol,
vol. 11,
pp. 628971,
2021.
| DOI: | 10.3389/fimmu.2020.628971 |
F. Heinrich,
C. Romich,
T. Zimmermann,
I. Kniep,
A. Fitzek,
S. Steurer,
M. Glatzel,
D. Nörz,
T. Günther,
M. Czech-Sioli,
N. Fischer,
A. Grundhoff,
M. Lütgehetmann and
B. Ondruschka,
"Dying of VOC-202012/01 - multimodal investigations in a death case of the SARS-CoV-2 variant",
Int J Legal Med,
pp. 1-10,
2021.
| DOI: | 10.1007/s00414-021-02618-8 |
S. Deinhardt-Emmer,
D. Wittschieber,
J. Sanft,
S. Kleemann,
S. Elschner and
e. a. Haupt,
"Early postmortem mapping of SARS-CoV-2 RNA in patients with COVID-19 and the correlation with tissue damage",
Elife,
vol. 10,
2021.
L. Gieselmann and
et al,
"Effective high-throughput isolation of fully human antibodies targeting infectious pathogens",
Nature Protocols,
2021.
| DOI: | 10.1038/s41596-021-00554-w |
A. Deckert,
S. Anders,
M. Allegri and
others,
"Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial",
Trials,
vol. 22,
no. 1,
2021.
| DOI: | 10.1186/s13063-020-04982-z |
| Datei: | https://doi.org/10.1186/s13063-020-04982-z |
A. Deckert,
S. Anders,
M. Allegri and
et al,
"Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial",
Trials,
vol. 22,
no. 1,
2021.
| DOI: | 10.1186/s13063-020-04982-z |
A. Deckert,
S. Anders,
M. Allegri and
others,
"Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): study protocol for a two-factorial randomized controlled multi-arm trial with cluster sampling",
Trials,
vol. 22,
no. 1,
2021.
| DOI: | 10.1186/s13063-021-05619-5 |
| Datei: | https://doi.org/10.1186/s13063-021-05619-5 |
A. Deckert,
S. Anders,
M. De Allegri and
et al,
"Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): study protocol for a two-factorial randomized controlled multi-arm trial with cluster sampling",
Trials,
vol. 22,
no. 1,
2021.
| DOI: | 10.1186/s13063-021-05619-5 |
P. Beschoner,
M. Jarczok,
M. Kempf,
K. Weimer,
F. Geiser,
N. Hiebel,
Y. Erim,
E. Morawa,
S. Steudte-Schmiedgen,
C. Albus and
L. Jerg-Bretzke,
"egePan-VOICE study on the psychosocial burden of the Covid-19 pandemic among medical technical assistants",
Z Psychosom Med Psychother,
2021.
S. Zellmer,
M. Kahn,
A. Ebigbo and
et al,
"Ein Jahr Covid-19: Testung, Verwendung von Schutzausrüstung und Auswirkungen auf die Gastrointestinale Endoskopie in Deutschland",
Z Gastroenterol,
vol. 59,
no. 8,
2021.
| DOI: | 10.1055/s-0041-1734140 |
M. Kahn,
S. Zellmer,
A. Ebigbo and
et al,
"Ein Jahr Covid-19: Testung, Verwendung von Schutzausrüstung und Auswirkungen auf die Gastrointestinale Endoskopie in Deutschland",
Z Gastroenterol,
vol. 59,
no. 12,
2021.
| DOI: | 10.1055/a-1649-8184 |
B. Jensen,
N. Luebke,
T. Feldt and
et al,
"Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany",
Lancet Reg Health Eur,
vol. 8,
2021.
| DOI: | 10.1016/j.lanepe.2021.100164 |
B. Jensen,
N. Luebke,
T. Feldt,
V. Keitel,
T. Brandenburger,
D. Kindgen-Milles,
M. Lutterbeck,
N. F. Freise,
D. Schoeler,
R. Haas,
A. Dilthey,
O. Adams,
A. Walker,
J. Timm and
T. Luedde,
"Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany",
The Lancet regional health. Europe,
vol. 8,
pp. 100164,
2021.
Abstract:
BACKGROUND Monoclonal antibodies (mAb) have been introduced as a promising new therapeutic approach against SARS-CoV-2. At present, there is little experience regarding their clinical effects in patient populations underrepresented in clinical trials, e.g. immunocompromised patients. Additionally, it is not well known to what extent SARS-CoV-2 treatment with monoclonal antibodies could trigger the selection of immune escape viral variants. METHODS After identifying immunocompromised patients with viral rebound under treatment with bamlanivimab, we characterized the SARS-CoV-2-isolates by whole genome sequencing. Viral load measurements and sequence analysis were performed consecutively before and after bamlanivimab administration. FINDINGS After initial decrease of viral load, viral clearance was not achieved in five of six immunocompromised patients treated with bamlanivimab. Instead, viral replication increased again over the course of the following one to two weeks. In these five patients, the E484K substitution - known to confer immune escape - was detected at the time of viral rebound but not before bamlanivimab treatment. INTERPRETATION Treatment of SARS-CoV-2 with bamlanivimab in immunocompromised patients results in the rapid development of immune escape variants in a significant proportion of cases. Given that the E484K mutation can hamper natural immunity, the effectiveness of vaccination as well as antibody-based therapies, these findings may have important implications not only for individual treatment decisions but may also pose a risk to general prevention and treatment strategies. FUNDING All authors are employed and all expenses covered by governmental, federal state, or other publicly funded institutions.
| DOI: | 10.1016/j.lanepe.2021.100164 |
Abstract:
BACKGROUND Monoclonal antibodies (mAb) have been introduced as a promising new therapeutic approach against SARS-CoV-2. At present, there is little experience regarding their clinical effects in patient populations underrepresented in clinical trials, e.g. immunocompromised patients. Additionally, it is not well known to what extent SARS-CoV-2 treatment with monoclonal antibodies could trigger the selection of immune escape viral variants. METHODS After identifying immunocompromised patients with viral rebound under treatment with bamlanivimab, we characterized the SARS-CoV-2-isolates by whole genome sequencing. Viral load measurements and sequence analysis were performed consecutively before and after bamlanivimab administration. FINDINGS After initial decrease of viral load, viral clearance was not achieved in five of six immunocompromised patients treated with bamlanivimab. Instead, viral replication increased again over the course of the following one to two weeks. In these five patients, the E484K substitution - known to confer immune escape - was detected at the time of viral rebound but not before bamlanivimab treatment. INTERPRETATION Treatment of SARS-CoV-2 with bamlanivimab in immunocompromised patients results in the rapid development of immune escape variants in a significant proportion of cases. Given that the E484K mutation can hamper natural immunity, the effectiveness of vaccination as well as antibody-based therapies, these findings may have important implications not only for individual treatment decisions but may also pose a risk to general prevention and treatment strategies. FUNDING All authors are employed and all expenses covered by governmental, federal state, or other publicly funded institutions.
L. Ruhl and
et al,
"Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks",
Signal transduction and targeted therapy,
vol. 6,
pp. 418,
2021.
| DOI: | 10.1038/s41392-021-00819-6 |
[German]
S. Stillfried,
P. Boor and
D. PANDEMIcs,
"Entwicklung eines kooperativen Obduktionsnetzwerks aus Pathologie, Neuropathologie und Rechtsmedizin",
Pathologe,
pp. 1-5,
2021.
| DOI: | 10.1007/s00292-021-01004-w |
F. Zack,
S. Nigbur,
J. Manhart,
H. Derani,
D. Boy,
V. Kolbe and
A. Büttner,
"Erste Ergebnisse der Obduktionen der im Zusammenhang mit den SARS-CoV-2-Infektionen Verstorbenen aus der Unimedizin Rostock",
Ärztebl Meckl-Vorpom,
vol. 31,
pp. 125-128,
2021.
A. Revet,
J. Hebebrand,
D. Anagnostopoulos,
L. Kehoe,
C. Child,
S. Bender and
P. Klauser,
"ESCAP CovCAP survey of heads of academic departments to assess the perceived initial (April/May 2020) impact of the COVID-19 pandemic on child and adolescent psychiatry services",
European Child & Adolescent Psychiatry,
2021.
| DOI: | 10.1007/s00787-020-01699-x |
R. Wagner,
D. Peterhoff,
S. Beileke and
et al,
"Estimates and determinants of SARS-Cov-2 seroprevalence and infection fatality ratio using latent class analysis: The population-based Tirschenreuth study in the hardest-hit German county in spring 2020",
Viruses,
vol. 13,
no. 6,
2021.
| DOI: | 10.3390/v13061118 |
| Datei: | https://doi.org/10.3390/v13061118 |
T. C. Jones and
et al,
"Estimating infectiousness throughout SARS-CoV-2 infection course",
Science (New York, N.Y.),
2021.
| DOI: | 10.1126/science.abi5273 |
K. A. Eberhardt and
et al,
"Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG",
Microorganisms,
vol. 9,
2021.
| DOI: | 10.3390/microorganisms9040733 |
M. Korenkov,
N. Poopalasingam,
M. Madler and
et al,
"Evaluation of a Rapid Antigen Test To Detect SARS-CoV-2 Infection and Identify Potentially Infectious Individuals",
J Clin Microbiol,
vol. 59,
no. 9,
2021.
| DOI: | 10.1128/JCM.00896-21 |
T. Toptana,
L. Eckermann,
A. E. Pfeiffer and
et al,
"Evaluation of a SARS-CoV-2 rapid antigen test: Potential to help reduce community spread?",
J Clin Virol,
vol. 135,
2021.
| DOI: | 10.1016/j.jcv.2020.104713 |
M. Metzendorf and
R. M. Featherstone,
"Evaluation of the comprehensiveness, accuracy and currency of the Cochrane COVID-19 Study Register for supporting rapid evidence synthesis production",
Res Synth Methods,
Jun.
2021.
| DOI: | 10.1002/jrsm.1501 |
J. Hildebrandt,
M. I. Metzendorf and
T. Jakob,
"Evaluierung der deutschen Datenbank Current Contents Medizin (CC MED) als potenzielle Datenquelle für das Cochrane COVID-19-Studienregister",
GMS Med Inform Biom Epidemiol,
vol. 17,
no. 3,
pp. Doc12,
2021.
| DOI: | 10.3205/mibe000226 |
| Datei: |
M. Popp,
P. Kranke,
P. Meybohm,
M. Metzendorf,
N. Skoetz,
M. S. Stegemann and
S. Weibel,
"Evidence on the efficacy of ivermectin for COVID-19: another story of apples and oranges",
BMJ Evid Based Med,
vol. 2021,
pp. bmjebm-2021-111791,
2021.
| DOI: | 10.1136/bmjebm-2021-111791 |
J. Wachinger,
M. Schirmer,
N. Täuber and
et al,
"Experiences with opt-in, at-home screening for SARS-CoV-2 at a primary school in Germany: an implementation study",
BMJ Paediatr Open,
vol. 5,
no. 1,
2021.
| DOI: | 10.1136/bmjpo-2021-001262 |
| Datei: | https://doi.org/10.1136/bmjpo-2021-001262 |
[en]
J. M. Tielker,
J. P. Weber,
S. T. Simon,
C. Bausewein,
S. Stiel and
N. Schneider,
"Experiences, challenges and perspectives for ensuring end-of-life patient care: A national online survey with general practitioners in Germany",
PLOS ONE,
vol. 16,
no. 7,
pp. e0254056,
Jul.
2021.
Abstract:
Background The SARS-CoV-2 (COVID-19) pandemic is posing major challenges for health care systems. In Germany, one such challenge has been that adequate palliative care for the severely ill and dying (with and without COVID-19), as well as their loved ones, has not been available at all times and in all settings., the pandemic has underlined the significance of the contribution of general practitioners (GPs) to the care of severely ill and dying patients. Objectives To describe GPs’ experiences, challenges and perspectives with respect to end-of-life care during the first peak of the pandemic (spring 2020) in Germany. Materials and methods In November and December 2020, a link to an Unipark online survey was sent to GPs registered on nationwide distribution lists. Results In total, 410 GPs responded; 61.5% indicated that the quality of their patients’ end-of-life care was maintained throughout the pandemic, 36.8% reported a decrease in quality compared to pre-pandemic times. Of the GPs who made home visits to severely ill and dying patients, 61.4% reported a stable number of visits, 28.5% reported fewer visits. 62.7% of the GPs reported increased telephone contact and reduced personal contact with patients; 36.1% offered video consultations in lieu of face-to-face contact. The GPs reported that relatives were restricted (48.5%) or prohibited from visiting (33.4%) patients in nursing homes. They observed a fear of loneliness among patients in nursing homes (91.9%), private homes (87.3%) and hospitals (86.1%). Conclusions The present work provides insights into the pandemic management of GPs and supports the development of a national strategy for palliative care during a pandemic. To effectively address end-of-life care, GPs and palliative care specialists should be involved in COVID-19 task forces on micro, meso and macro levels of health care.
| DOI: | 10.1371/journal.pone.0254056 |
| Datei: | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0254056 |
Abstract:
Background The SARS-CoV-2 (COVID-19) pandemic is posing major challenges for health care systems. In Germany, one such challenge has been that adequate palliative care for the severely ill and dying (with and without COVID-19), as well as their loved ones, has not been available at all times and in all settings., the pandemic has underlined the significance of the contribution of general practitioners (GPs) to the care of severely ill and dying patients. Objectives To describe GPs’ experiences, challenges and perspectives with respect to end-of-life care during the first peak of the pandemic (spring 2020) in Germany. Materials and methods In November and December 2020, a link to an Unipark online survey was sent to GPs registered on nationwide distribution lists. Results In total, 410 GPs responded; 61.5% indicated that the quality of their patients’ end-of-life care was maintained throughout the pandemic, 36.8% reported a decrease in quality compared to pre-pandemic times. Of the GPs who made home visits to severely ill and dying patients, 61.4% reported a stable number of visits, 28.5% reported fewer visits. 62.7% of the GPs reported increased telephone contact and reduced personal contact with patients; 36.1% offered video consultations in lieu of face-to-face contact. The GPs reported that relatives were restricted (48.5%) or prohibited from visiting (33.4%) patients in nursing homes. They observed a fear of loneliness among patients in nursing homes (91.9%), private homes (87.3%) and hospitals (86.1%). Conclusions The present work provides insights into the pandemic management of GPs and supports the development of a national strategy for palliative care during a pandemic. To effectively address end-of-life care, GPs and palliative care specialists should be involved in COVID-19 task forces on micro, meso and macro levels of health care.
J. M. Tielker,
J. P. Weber,
S. T. Simon,
C. Bausewein,
S. Stiel and
N. Schneider,
"Experiences, challenges and perspectives for ensuring end-of-life patient care: A national online survey with general practitioners in Germany",
PLoS ONE,
vol. 16,
no. 7,
pp. e0254056,
2021.
| DOI: | 10.1371/journal.pone.0254056 |
M. Muenchhoff,
A. Graf,
S. Krebs and
et al,
"Genomic epidemiology reveals multiple introductions of SARS-CoV-2 followed by community and nosocomial spread, Germany, February to May 2020",
Euro Surveill,
vol. 26,
no. 43,
2021.
| DOI: | 10.2807/1560-7917.ES.2021.26.43.2002066 |
| Datei: | https://doi.org/10.2807/1560-7917.ES.2021.26.43.2002066 |
S. Thun,
J. Sass and
A. Bartschke,
"German Corona Consensus Datensatz (GECCO): Verbesserter Austausch von COVID-19-Forschungsdaten",
kma - Klinik Management aktuell,
vol. 26,
no. 06,
pp. 55—56,
2021.
| DOI: | 10.1055/s-0041-1731187 |
A. Gruber,
T. Firsching,
J. Trimpert and
K. Dietert,
"Hamster models of COVID-19 pneumonia reviewed: How human can they be?",
Vet Pathol,
2021.
M. Schmidt,
S. Kugai,
N. Amarell and
B. Weltermann,
"Handlungsfähigkeit von Hausärzt*innen während der COVID-19-Pandemie",
DocV-15-05,
2021.
| DOI: | 10.3205/21degam086 |
J. A. F. Klein,
L. J. Krüger,
F. Tobian and
et al,
"Head-to-head performance comparison of self-collected nasal versus professional-collected nasopharyngeal swab for a WHO-listed SARS-CoV-2 antigen-detecting rapid diagnostic test",
Med Microbiol Immunol,
vol. 210,
no. 4,
2021.
| DOI: | 10.1007/s00430-021-00710-9 |
| Datei: | https://doi.org/10.1007/s00430-021-00710-9 |
S. Hadzibegovic,
A. Lena,
T. Churchill,
J. Ho,
S. Potthoff,
C. Denecke,
L. Rösnick,
K. Heim,
M. Kleinschmidt,
L. Sander and
others,
"Heart failure with preserved ejection fraction according to the HFA-PEFF score in COVID-19 patients: clinical correlates and echocardiographic findings",
Eur J Heart Fail,
vol. 23,
no. 11,
pp. 1891—1902,
2021.
| DOI: | 10.1002/ejhf.2210 |
R. Groß and
et al,
"Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants",
EBioMedicine,
vol. 75,
pp. 103761,
2021.
| DOI: | 10.1016/j.ebiom.2021.103761 |
M. Tenbusch,
S. Schumacher,
E. Vogel and
et al,
"Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2",
Lancet Infect Dis,
vol. 21,
no. 9,
2021.
| DOI: | 10.1016/S1473-3099(21)00420-5 |
M. Rössler,
J. Jacob,
L. Risch,
F. Tesch,
D. Enders,
D. Wende,
R. Jucknewitz,
O. Weidinger,
M. Batram,
P. Ballesteros,
S. Baßler,
D. Hertle,
U. Repschläger,
N. Richter,
C. Schulte,
A. Schramm,
F. Sobik,
M. Treskova-Schwarzbach,
S. Scholz,
J. Walker and
others,
"Hierarchisierung von Risikofaktoren für schwere COVID-19-Erkrankungsverläufe im Kontext der COVID-19-Schutzimpfungen",
2021.
| DOI: | 10.25646/8405.2 |